SERZONE
LOE ApproachingNDAORALTABLET
Approved
Dec 1994
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 12h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SERZONE is an oral small-molecule antidepressant approved by Bristol Myers Squibb in 1994. The drug's specific mechanism of action and indicated therapeutic area are not disclosed in available data. The product is currently in loss-of-exclusivity phase, indicating mature market status.
LOE Approaching
As LOE approaches, commercial teams are likely in maintenance or transition mode with reduced headcount and limited growth investment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
SERZONE offers limited career advancement given zero linked job openings and approaching LOE status. Working on this asset is primarily a maintenance role focused on managing market decline rather than driving growth or innovation.
Brand ManagerField Sales Representative
Worked on SERZONE at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.